secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001193125-24-092522
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks
--------------------------------------------------------------------------------

- Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.
- No ≥ Grade 3 non-hematologic treatment-related adverse events; well tolerated with no dose reductions.
- ELVN-001 at ≥40mg QD shows superior target coverage vs 2nd-gen TKIs; PK supports once-daily dosing with no food effect.
- 89% of all enrolled patients remain on study; maximum tolerated dose not yet identified.
- Company hosting virtual event with key opinion leaders at 8:00 AM ET today to discuss data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524092522/0001193125-24-092522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524092522/d763719d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-092522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer